<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1870-249X</journal-id>
<journal-title><![CDATA[Journal of the Mexican Chemical Society]]></journal-title>
<abbrev-journal-title><![CDATA[J. Mex. Chem. Soc]]></abbrev-journal-title>
<issn>1870-249X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Química de México A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1870-249X2017000100041</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Synthesis and Biological Evaluation of New 3,4-diarylmaleimides as Enhancers (modulators) of Doxorubicin Cytotoxic Activity on Cultured Tumor Cells from a Real Case of Breast Cancer]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gutierrez-Cano]]></surname>
<given-names><![CDATA[Jessica R.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Nahide]]></surname>
<given-names><![CDATA[Pradip D.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramadoss]]></surname>
<given-names><![CDATA[Velayudham]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Satkar]]></surname>
<given-names><![CDATA[Yuvraj]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ortiz-Alvarado]]></surname>
<given-names><![CDATA[Rafael]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alba-Betancourt]]></surname>
<given-names><![CDATA[Clara]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mendoza-Macías]]></surname>
<given-names><![CDATA[Claudia L.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Solorio-Alvarado]]></surname>
<given-names><![CDATA[César R.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Guanajuato Departamento de Química División de Ciencias Naturales y Exactas]]></institution>
<addr-line><![CDATA[Cerro de la Venada Guanajuato]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Guanajuato Departamento de Farmacia, División de Ciencias Naturales y Exactas ]]></institution>
<addr-line><![CDATA[Noria Alta Guanajuato]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Michoacana de San Nicolás de Hidalgo Facultad de Químico Farmacobiología ]]></institution>
<addr-line><![CDATA[Tzintzuntzan Michoacán]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2017</year>
</pub-date>
<volume>61</volume>
<numero>1</numero>
<fpage>41</fpage>
<lpage>49</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1870-249X2017000100041&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1870-249X2017000100041&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1870-249X2017000100041&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: A series of new 3,4-diarylmaleimides were synthesized in an optimized and efficient lineal sequence of three steps, starting from commercial maleimide. The biological evaluation of these compounds as enhancers (activity modulators) in the co-administration with doxorubicin treatment in breast cancer cells directly obtained from a patient, were essayed. The cancerous tissue BT026-512N was provided by the National Institute of Cancerology (INCAN) of México. This tissue was obtained by biopsy from a patient diagnosed with stage IIB ductal breast cancer. The results obtained in the assays, show decreased cell viability on the cultured cells for all of the maleimides synthesized in combinatorial administration with doxorubicin. The highest mortality effect was determined for maleimides 9 and 29 increased in close to three times the effect compared with treatment using only doxorubicin. Based on previous functionalized maleimides core reports and Molinspiration chemoinformatic analysis, these results could possibly point out to the Pg-p glycoprotein as bio-molecular action target of maleimides by kinase phosphorylation-inhibition, although more experimental data is necessary.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: Una serie de nuevas 3,4-diarilmaleimidas fueron sintetizadas en una secuencia lineal optimizada y eficiente de tres pasos, iniciando de maleimida comercial. La evaluación biológica de estos compuestos como potenciadores (moduladores de actividad) en la coadministración con el tratamiento de doxorrubicina en un caso de células obtenidas de un paciente con cáncer de mama, fueron ensayados. El tejido canceroso BT026-512N fue provisto por el Instituto Nacional de Cancerología (INCAN) de México. Este tejido fue obtenido por biopsia de un paciente diagnosticado con cáncer de mama izquierdo con infiltración ductal en etapa IIB. Los resultados obtenidos en los ensayos muestran de manera general incremento en la mortalidad celular de los cultivos para todas las maleimidas sintetizadas en administración combinatoria con doxorrubicina. El efecto de mortalidad más alto fue determinado para las maleimidas 9 y 29 incrementando cerca de tres veces el efecto comparado con el tratamiento utilizando solamente doxorrubicina. Con base a reportes previos del núcleo funcional de las maleimidas así como un análisis quimioinformático en Molinspiration, estos resultados pudieran sugerir a la glicoproteína Pg-p como blanco biomolecular de acción de las maleimidas por la inhibición de la fosforilación de la cinasa, aunque más experimentos son necesarios para corroborarlos.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Cáncer de mama]]></kwd>
<kwd lng="es"><![CDATA[maleimida]]></kwd>
<kwd lng="es"><![CDATA[doxorrubicina]]></kwd>
<kwd lng="es"><![CDATA[tratamiento sinérgico para cáncer]]></kwd>
<kwd lng="en"><![CDATA[Breast cancer, Maleimide]]></kwd>
<kwd lng="en"><![CDATA[Doxorubicin]]></kwd>
<kwd lng="en"><![CDATA[synergistic cancer treatment]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kamangar]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Dores]]></surname>
<given-names><![CDATA[G.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[W.F.]]></given-names>
</name>
</person-group>
<source><![CDATA[J. Clin. Oncol]]></source>
<year>2006</year>
<volume>24</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>2137-50</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Binaschi]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Bigioni]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Cipollone]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Rossi]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Goso]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Maggi]]></surname>
<given-names><![CDATA[C.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Capranico]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Animati]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<source><![CDATA[Anti-Cancer Agents]]></source>
<year>2001</year>
<volume>1</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>113-30</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Minotti]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Menna]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Salvatorelli]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Cairo]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Gianni]]></surname>
<given-names><![CDATA[L. Anthracyclines.]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacol Rev]]></source>
<year>2004</year>
<volume>56</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>185-229</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Tasaka]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[K.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[M.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Karnofsk]]></surname>
<given-names><![CDATA[D.A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer]]></source>
<year>1967</year>
<volume>20</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>333-53</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arcamone]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Cassinelli]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Fantini]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Grein]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Orezzi]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Pol]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Spalla]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<source><![CDATA[Biotechnol Bioeng]]></source>
<year>1969</year>
<volume>11</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1101-10</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goldenberg]]></surname>
<given-names><![CDATA[G.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Blair]]></surname>
<given-names><![CDATA[G.W.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Res]]></source>
<year>1986</year>
<volume>46</volume>
<page-range>2978-83</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rhinehart]]></surname>
<given-names><![CDATA[J.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[R.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Balcerzak]]></surname>
<given-names><![CDATA[S.P.]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Intern Med]]></source>
<year>1974</year>
<volume>81</volume>
<page-range>475-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lehne]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr Drug Targets]]></source>
<year>2000</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>85-99</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kartner]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Riordan]]></surname>
<given-names><![CDATA[J.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Ling]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<source><![CDATA[Science]]></source>
<year>1983</year>
<volume>221</volume>
<page-range>1285-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsuruo]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Iida]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Tsukagoshi]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Sakurai]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer]]></source>
<year>1981</year>
<volume>41</volume>
<page-range>1967-72</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[P.Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[I.L.K.]]></given-names>
</name>
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[C.S.W.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[X.Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Chow]]></surname>
<given-names><![CDATA[L.M.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Wan]]></surname>
<given-names><![CDATA[S.B.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Med Chem]]></source>
<year>2010</year>
<volume>53</volume>
<page-range>5108-20</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[M.]]></surname>
<given-names><![CDATA[. Lacroix]]></given-names>
</name>
</person-group>
<source><![CDATA[Endocr RelatCancer]]></source>
<year>2006</year>
<volume>13</volume>
<page-range>1033-67</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lipinski]]></surname>
<given-names><![CDATA[C. A]]></given-names>
</name>
<name>
<surname><![CDATA[Lombardo]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Dominy]]></surname>
<given-names><![CDATA[B. W.]]></given-names>
</name>
<name>
<surname><![CDATA[Feeney]]></surname>
<given-names><![CDATA[P. J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Adv Drug Deliver Rev]]></source>
<year>2001</year>
<volume>64</volume>
<page-range>3-26</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bin]]></surname>
<given-names><![CDATA[J. W.]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[I. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[Z. X.]]></given-names>
</name>
<name>
<surname><![CDATA[Xing]]></surname>
<given-names><![CDATA[L. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Biao]]></surname>
<given-names><![CDATA[W. S.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Med Chem]]></source>
<year>2013</year>
<volume>56</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>9057-70</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="">
<source><![CDATA[Miscreen-Molinspiration Fragment-based Virtual Screening Engine]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[C. W.]]></given-names>
</name>
<name>
<surname><![CDATA[Asai]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[J.H.]]></given-names>
</name>
<name>
<surname><![CDATA[Kishimura]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Mori]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Katayama]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<source><![CDATA[Tumor Biol]]></source>
<year>2015</year>
<volume>37</volume>
<page-range>1901-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meyers]]></surname>
<given-names><![CDATA[M. B.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Commun]]></source>
<year>1989</year>
<volume>1</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>233-41</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
